Lupin's US Generics Turn Corner, Upcoming Launches To Fuel Momentum
Executive Summary
A recovery in the US, aided by abating pricing pressure and portfolio exits by some large players, augurs well for Indian firm Lupin, but impending new launches including levothyroxine will need to deliver to sustain US momentum.
You may also be interested in...
Indian Pharma Regaining Form, Helped By Easing US Price Pressures
Indian drug makers are looking in much better shape as US pricing pressures ease and the domestic market regains its double-digit growth, analysts say.
Lupin Launches First Ranexa Rival In US
In line with its strategy to transition to more complex generics, Lupin has announced the exclusive launch of its generic version of Gilead Science’s Ranexa 500mg and 1,000mg extended-release tablets in the US.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.